查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983691

基因检测板市场：按产品类型、技术、应用和最终用户划分－2026-2032年全球市场预测

Gene Panel Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因检测市场价值将达到 37.7 亿美元，到 2026 年将成长到 41.8 亿美元，到 2032 年将达到 78.8 亿美元，复合年增长率为 11.08%。

主要市场统计数据
基准年 2025 37.7亿美元
预计年份：2026年 41.8亿美元
预测年份 2032 78.8亿美元
复合年增长率 (%) 11.08%

本报告清楚概述了基因检测市场的现状，重点关注技术融合、临床应用以及检测实验室和公司领导者面临的策略选择。

基因组检测生态系统正处于转折点，其驱动力包括技术成熟、临床应用以及不断变化的监管预期。本执行摘要概述了当前形势，并重点介绍了影响产品开发人员、检查室管理人员和商业领导者策略规划的关键主题。本报告的分析观点着重于转化价值、互通性以及将基因组学见解转化为临床和商业性成果的途径。

平台成熟、自动化进步以及不断变化的监管预期，是如何重塑整个基因检测生态系统中价值创造和应用的路径的？

近年来，随着平台创新和新的临床应用案例的逐步成熟，基因panel的格局发生了重塑。定序化学和样品製备技术的进步降低了检测的变异性，提高了对低表达靶点的灵敏度，推动了从单基因检测到多重和多基因检测的转变。这种技术革新正在推动价值提案的更广泛重构。如今，评估平台的标准不仅包括其处理能力，还包括其整合工作流程、与自动化系统的兼容性以及对下游资讯学和彙报的支援能力。

评估关税如何改变基因面板相关人员的供应链重组和筹资策略，改变其采购动态和业务永续营运。

2025年美国关税政策对依赖国际供应链采购试剂、定序设备及相关硬体的公司提出了结构性挑战。关税提高了进口零件的相对成本，促使买家重新评估其製造地，从而影响了筹资策略和供应商谈判。为此，许多企业采取了双重采购策略，并加强了与国内供应商的沟通，以维持利润率和交货时间。对于设备製造商而言，关税促使他们重新评估零件标准化，以减少对受关税影响零件的依赖。

全面的細項分析揭示了产品类型、技术、临床应用和不同终端使用者群体的明确需求因素。

对市场区隔的详细分析揭示了不同产品类型、技术、应用和最终用户群体在采用模式和价值因素方面的差异。就产品类型而言，市场可细分为客製化检测板、平台解决方案和现成产品线。客製化检测板包括针对复杂诊断挑战优化的多基因构建体，以及用于靶向、高灵敏度检测的单基因检测板。平台解决方案的特点是整合了可实现端到端自动化的系统和支援模组化工作流程的样品製备盒。现成检测板正变得越来越专业化，包括血液学检测板、感染疾病板和固态肿瘤板，旨在简化验证和临床报告流程。

美洲、欧洲、中东和非洲以及亚太地区的市场动态和法规环境会影响招募重点和策略市场进入决策。

区域趋势带来了独特的营运环境、法律规范和临床重点，这些都会影响产品开发和打入市场策略。在美洲，临床效用与保险报销的一致性至关重要，这促使转化研究获得大量投资，并在肿瘤临床路径中广泛采用多基因检测组合。北美检查室通常优先考虑扩充性和监管认证，因此倾向于购买整合平台和经过检验的现成检测组合，以加速临床部署。这种环境也促进了诊断开发商与临床网路之间的合作，以支持实证医学的产生并与保险公司沟通。

企业级策略和竞争行为表明，平台整合伙伴关係和证据生成如何推动永续差异化。

关键的公司层面趋势揭示了成熟企业和新兴企业如何进行自我定位，以确保其长期竞争力。市场领导日益关注仪器、耗材和资讯学的整合平台生态系统，以减少检验和临床部署过程中的阻力。策略性措施通常包括扩展服务和支援范围、建立定期试剂供应计划以及开发标准化的生物资讯流程，以提高可重复性和监管可追溯性。这些倡议降低了高通量检查室采用端到端解决方案的门槛，同时也使供应商能够透过耗材和软体订阅获得持续收入。

为诊断开发人员和检查室管理人员提供实用策略指南，以建立强大的价值链、加速临床部署并优化平台价值提案。

为了将市场复杂性转化为竞争优势，产业领导者应采取组合策略，平衡平台投资与满足临床医生和检查室需求的特定应用产品和服务。优先开发整合工作流程，最大限度地减少人工操作时间并简化检验，同时提供模组化选项，例如样品製备盒，以满足客户对柔软性的需求。投资于透明且检验的生物资讯流程和报告工具，以减少解读差异并支持监管申报。

为了确保提供切实可行的见解，我们采用透明且可重复的调查方法，将与关键相关人员的访谈与严格的二次检验和迭代细分测试相结合。

本研究整合了定性访谈、文献综述和系统检验，旨在建构对基因检测生态系统的全面理解。主要研究包括对检查室管理人员、临床医生、平台供应商和供应链专家进行结构化访谈，以收集关于基因检测应用障碍、营运需求和检验要求的第一手资料。二级资讯来源包括同行评审文献、监管指导文件和企业资讯披露，以对技术能力和产品定位进行多角度检验。

透过整合强调技术证据和营运韧性应如何协调一致的结论，我们将基因面板创新转化为可持续的临床和商业性影响。

总之，目前基因检测技术的特点是平台功能、临床需求和监管要求之间正迅速融合。定序和检测化学技术的进步正在拓展其临床应用范围，同时也提高了证据生成、可重复性和对整合工作流程支援的要求。供应链趋势和区域监管差异进一步增加了营运复杂性，任何商业策略都必须积极应对这些挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基因检测板市场：依产品类型划分

  • 自订面板
    • 多基因检测
    • 单基因检测
  • 平台
    • 整合系统
    • 样品製备工具包
  • 预製板
    • 血液疾病检测
    • 感染疾病专家组
    • 固态肿瘤组

第九章 基因检测市场：依技术划分

  • 微阵列
    • 比较基因组杂合反应阵列
    • SNP晶片
  • NGS
    • 扩增子序列
    • 混合捕获序列
  • PCR
    • ddPCR
    • qPCR
  • 桑格定序

第十章 基因检测板市场：依应用划分

  • 感染疾病
    • 细菌检测板
    • 病毒面板
  • 肿瘤学
    • 液态生物检体组合
    • 固态肿瘤组
  • 药物基因体学
  • 罕见疾病
    • 遗传疾病检测
    • 神经系统疾病组

第十一章 基因检测市场：依最终用户划分

  • 学术和研究机构
  • 诊断检测实验室
  • 医院和诊所
  • 製药和生物技术公司

第十二章 基因检测板市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 基因检测板市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 基因检测板市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基因检测市场

第十六章：中国基因检测市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • myGenomics
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • Novogene Co, Ltd.
  • PerkinElmer, Inc.
  • PrimBio Research Institute
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
Product Code: MRR-FF012EDC38AC

The Gene Panel Market was valued at USD 3.77 billion in 2025 and is projected to grow to USD 4.18 billion in 2026, with a CAGR of 11.08%, reaching USD 7.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.77 billion
Estimated Year [2026] USD 4.18 billion
Forecast Year [2032] USD 7.88 billion
CAGR (%) 11.08%

A clear framing of the contemporary gene panel landscape highlighting technological convergence clinical adoption and the strategic choices facing laboratory and commercial leaders

The gene panel ecosystem is at an inflection point driven by technological maturation, clinical adoption, and shifting regulatory expectations. This executive summary introduces the landscape and frames the critical themes that shape strategic planning for product developers, laboratory directors, and commercial leaders. It establishes the analytical lens used throughout the report, emphasizing translational value, interoperability, and the pathways that convert genomic insights into clinical and commercial outcomes.

Early adopters and established players alike are navigating a mix of converging forces: innovation in sequencing and assay design, rising demand for precision diagnostics across oncology and infectious disease, and the need for robust laboratory workflows that support high-throughput, clinically accredited testing. As laboratories integrate multigene approaches alongside targeted single-gene assays, stakeholders must balance flexibility with reproducibility, and research-driven customization with regulatory-grade validation. The introduction sets expectations for the report's depth, highlights the importance of actionable segmentation, and outlines how subsequent sections will translate market dynamics into strategic choices for leaders and investors.

How platform maturation automation advances and evolving regulatory expectations are recalibrating value creation and adoption pathways across the gene panel ecosystem

Over the last several years the landscape for gene panels has reconfigured as platform innovation and new clinical use cases have matured in parallel. Advances in sequencing chemistry and library preparation have reduced assay variability and enhanced sensitivity for low-abundance targets, enabling a shift from single-gene tests toward multiplexed and multigene applications. This technological evolution has catalyzed a broader reorientation of value propositions: platforms are being evaluated not only for raw throughput but for integrated workflows, automation compatibility, and the ability to support downstream informatics and reporting.

Concurrently commercial dynamics have evolved. Diagnostic laboratories and hospital networks are increasingly prioritizing operational efficiency and interoperability, seeking platforms and consumables that facilitate rapid validation and scale. The emergence of hybrid capture and amplicon-based NGS approaches has expanded the range of applications, from solid tumor profiling to infectious disease surveillance and pharmacogenomics. Regulatory agencies are refining guidance around analytical and clinical validity, which shapes product development timelines and the evidentiary standards required for market adoption. As a result product developers are responding with predesigned panels optimized for specific indications while also offering customizable panels that allow clinicians and researchers to address unique diagnostic questions.

The interplay between platform providers and reagent kit manufacturers continues to reframe competitive dynamics. Integrated systems that deliver end-to-end solutions are capturing interest from high-throughput laboratories, whereas library prep kits and modular components retain appeal for centers seeking flexibility and cost control. Across applications a premium is being placed on reproducibility, speed to result, and the transparency of bioinformatic pipelines. Ultimately these transformative shifts are creating differentiated paths to adoption, where success depends on aligning technological capability with user workflows regulatory readiness and validated clinical utility.

Assessment of how tariff-driven supply chain realignments and sourcing strategies are reshaping procurement dynamics and operational resilience for gene panel stakeholders

United States tariff policy in 2025 introduced a structural consideration for firms that rely on international supply chains for reagents, sequencing instruments, and ancillary hardware. Tariffs influenced sourcing strategies and supplier negotiations by increasing the relative cost of imported components and prompting buyers to re-evaluate manufacturing footprints. In response many organizations initiated dual-sourcing strategies and intensified conversations with domestic suppliers to preserve margin and delivery timelines. For device manufacturers the tariffs incentivized a reevaluation of component standardization to reduce dependency on tariff-exposed parts.

Laboratories and service providers managing high-volume testing faced operational implications as procurement cycles lengthened and unit-level consumable planning became more complex. The need for inventory buffering increased lead times and required more sophisticated demand forecasting. These pressures accelerated interest in vendor-managed inventory models and long-term supply agreements that provide price predictability. Simultaneously, tariffs amplified the attractiveness of platform consolidation where fewer suppliers and integrated vendors could provide predictable, bundled pricing and support services that mitigate exposure to cross-border duty fluctuations.

From a strategic perspective organizations reassessed capital expenditure priorities and timeline sensitivities for instrument upgrades or validating new assays. The tariff environment also influenced partnership strategies: some companies sought regional manufacturing partnerships to localize production while others explored offshoring to jurisdictions with favorable trade agreements. Regulatory and reimbursement stakeholders observed these shifts as part of broader conversations about domestic manufacturing capacity and supply chain resilience, reinforcing the notion that supply chain strategy is now a core element of competitive positioning and risk mitigation for the gene panel sector.

Comprehensive segmentation analysis revealing distinct demand drivers across product typologies technologies clinical applications and the diverse spectrum of end users

A nuanced view of segmentation reveals differentiated adoption patterns and value drivers across product types, technologies, applications, and end users. When considering product type the market is organized across custom panels platform solutions and predesigned offerings. Custom panels span multigene constructs optimized for nuanced diagnostic questions as well as single gene panels that remain essential for targeted, high-sensitivity assays. Platforms are distinguished by integrated systems that provide end-to-end automation and library preparation kits that serve modular workflows. Predesigned panels are increasingly specialized with hematological panels infectious disease panels and solid tumor panels designed to streamline validation and clinical reporting.

Technology segmentation underscores distinct performance trade-offs and user preferences that inform procurement decisions. Microarray approaches continue to be relevant where comparative genomic hybridization arrays and SNP arrays offer cost-effective cytogenetic profiling. NGS technologies present a broad spectrum from amplicon sequencing suited for focused high-sensitivity targets to hybrid capture sequencing that supports comprehensive genomic coverage. PCR-based methods retain an essential role for rapid high-throughput screening with ddPCR and qPCR providing quantitative precision for low-input targets. Sanger sequencing remains a complementary orthogonal method for confirmatory testing where single-base resolution and established regulatory acceptance are critical.

Application-driven segmentation emphasizes clinical utility and laboratory workflow alignment. Infectious disease testing differentiates between bacterial panels and viral panels tailored for pathogen identification and resistance profiling. Oncology applications split into liquid biopsy panels enabling minimally invasive monitoring and solid tumor panels that support tissue-based molecular diagnostics. Pharmacogenomics centers on drug response panels that inform therapeutic selection while rare disease testing includes inherited disease panels and neurological disorder panels that require rigorous analytical validation and often necessitate bespoke interpretation pipelines. Across these applications, evidence generation and clinician engagement drive adoption curves.

End-user segmentation identifies distinct purchasing behaviors and evaluation criteria among academic and research institutes diagnostic laboratories hospitals and clinics and pharmaceutical and biotechnology companies. Academic and research institutes prioritize flexibility and exploratory capability with an emphasis on novel assay development and discovery. Diagnostic laboratories and clinical networks emphasize reproducibility accreditation and cost-per-test economics. Hospitals and clinics focus on integrated clinical workflows and rapid return of actionable results. Pharmaceutical and biotechnology companies seek panels that support companion diagnostic development translational studies and biomarker-enabled clinical trials. Understanding the interplay among these segmentation axes enables more precise product positioning and tailored commercial strategies.

Regional market dynamics and regulatory environments across the Americas Europe Middle East & Africa and Asia-Pacific that shape adoption priorities and strategic entry decisions

Regional dynamics introduce distinct operational environments regulatory frameworks and clinical priorities that influence product development and market entry strategies. In the Americas the emphasis is on clinical utility and reimbursement alignment, with significant investment in translational research and widespread integration of multigene panels in oncology pathways. North American laboratories often prioritize scalability and regulatory accreditation, shaping procurement decisions toward integrated platforms and validated predesigned panels that expedite clinical deployment. This environment also fosters collaborations between diagnostics developers and clinical networks to support evidence generation and payer engagement.

In Europe, Middle East & Africa regulatory heterogeneity and varied healthcare financing models drive region-specific adoption patterns. Several European markets place a premium on quality-assured workflows and harmonized testing standards, while emerging markets within the region balance cost containment with growing demand for infectious disease and rare disease diagnostics. The Middle East and Africa present both opportunities and challenges tied to infrastructure variability, prompting distributors and manufacturers to adapt service models and training programs to support local validation and implementation.

Asia-Pacific presents a diverse mosaic of advanced hubs and rapidly developing markets where capacity expansion and public health priorities shape demand. High-capacity centers in select markets pursue cutting-edge applications such as liquid biopsies and pharmacogenomics, whereas other markets prioritize infectious disease surveillance and cost-effective screening solutions. Regional supply chain considerations and local manufacturing initiatives influence procurement preferences, and collaborative public-private programs often catalyze broader access. Across all regions interoperability standards local regulatory expectations and reimbursement trajectories remain pivotal factors that influence strategic prioritization for manufacturers and service providers.

Company-level strategies and competitive behaviors showing how platform integration partnerships and evidence generation are driving sustainable differentiation

Key company-level trends reveal how incumbents and emerging entrants are positioning for long-term relevance. Market leaders increasingly emphasize platform ecosystems that integrate instruments consumables and informatics to reduce friction in validation and clinical implementation. Strategic initiatives commonly include expanding service and support offerings, establishing reagent continuity programs, and developing standardized bioinformatic pipelines to improve reproducibility and regulatory traceability. These moves lower barriers for high-throughput laboratories to adopt end-to-end solutions while enabling vendors to capture recurring revenue through consumables and software subscriptions.

Smaller and specialist companies are differentiating through focused verticalization and application-specific expertise. Firms that concentrate on hematological, infectious disease, or liquid biopsy panels invest in targeted clinical evidence and clinician education initiatives to accelerate acceptance. Collaboration remains a central motif as diagnostics firms partner with contract research organizations clinical laboratories and academic centers to co-develop panels, validate biomarkers, and support real-world evidence generation. Mergers and acquisitions continue to be a mechanism for consolidating complementary capabilities, acquiring specialized reagent technologies, or gaining regulatory footholds in new jurisdictions.

Across the competitive set there is sustained investment in quality management systems, regulatory affairs capacity, and post-market surveillance capabilities to meet evolving compliance expectations. Companies that succeed combine technical differentiation with robust commercialization frameworks that address validation pathways, payer engagement, and laboratory workflows. Intellectual property strategies focusing on assay chemistry, probe design, and bioinformatic algorithms provide defensive moats, while open collaboration on standards and interoperability can accelerate market expansion where adoption depends on cross-vendor compatibility.

Actionable strategic playbook for diagnostic developers and laboratory leaders to build resilient supply chains accelerate clinical adoption and optimize platform value propositions

To convert market complexity into competitive advantage, industry leaders should pursue a portfolio approach that balances platform investments with application-specific offerings that meet clinician and laboratory needs. Prioritize the development of integrated workflows that minimize hands-on time and simplify validation, while concurrently offering modular options such as library prep kits to serve customers who need flexibility. Invest in transparent and validated bioinformatic pipelines and reporting tools that reduce interpretation variability and support regulatory submissions.

Strengthen supply chain resilience by implementing diversified sourcing strategies, evaluating regional manufacturing partnerships, and exploring vendor-managed inventory models to stabilize availability and pricing. Align commercial strategies with clinical evidence generation by co-investing in targeted clinical studies and real-world data initiatives that demonstrate utility for oncology infectious disease and pharmacogenomics use cases. Engage payers and health systems early to understand reimbursement levers and to build health economic models that articulate value for result-driven care pathways.

Cultivate strategic partnerships across the ecosystem including laboratories, hospitals, and pharmaceutical companies to accelerate adoption and to integrate diagnostics into therapeutic decision-making. Maintain a rigorous regulatory and quality stance by expanding regulatory affairs expertise and establishing post-market surveillance to facilitate market entry and long-term compliance. Lastly focus on customer enablement through education programs technical support and implementation services that lower time-to-value and foster long-term customer loyalty.

Transparent and reproducible research methodology blending primary stakeholder interviews with rigorous secondary validation and iterative segmentation testing to ensure actionable insights

This research synthesizes primary qualitative interviews secondary literature mapping and methodical validation to construct a robust understanding of the gene panel ecosystem. Primary research involved structured interviews with laboratory directors clinicians platform vendors and supply chain specialists to capture first-hand insights on adoption barriers operational needs and validation requirements. Secondary sources included peer-reviewed literature regulatory guidance documents and company disclosures to triangulate technology capabilities and product positioning.

Data integrity was upheld through cross-validation across independent sources and by reconciling respondent perspectives with documented performance characteristics. Segmentation frameworks were iteratively tested with domain experts to ensure that product type, technology, application, and end-user categorizations reflect real-world procurement and clinical workflows. Limitations of the methodology include variations in publicly available evidence for newly launched products and the lag between clinical practice evolution and published validation studies. Where appropriate the analysis highlights areas requiring additional primary evidence to support definitive conclusions.

The research process emphasized transparency and reproducibility: methods, inclusion criteria, and interview guides are available to licensed purchasers seeking deeper methodological disclosure. Ethical practices and confidentiality protocols were followed throughout primary data collection to protect proprietary information while ensuring that synthesized insights remain actionable and generalizable for strategic decision-making.

Concluding synthesis that distills how technology evidence and operational resilience must align to convert gene panel innovation into sustained clinical and commercial impact

In conclusion the gene panel landscape is defined by accelerating convergence between platform capabilities clinical demand and regulatory expectations. Technological advancements in sequencing and assay chemistry have broadened clinical applicability while also raising the bar for evidence generation, reproducibility, and integrated workflow support. Supply chain dynamics and regional regulatory variability add layers of operational complexity that must be managed proactively as part of any commercial strategy.

Successful organizations will be those that align technical differentiation with validated clinical value, operational resilience, and tailored go-to-market approaches that reflect distinct end-user priorities and regional dynamics. Investment in robust bioinformatics, quality systems, and collaborative evidence-generation partnerships will be decisive factors in converting innovation into sustained adoption. The path forward requires disciplined execution across product development regulatory strategy and commercial engagement to realize the full potential of gene panels in advancing patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Panel Market, by Product Type

  • 8.1. Custom Panels
    • 8.1.1. Multigene Panels
    • 8.1.2. Single Gene Panels
  • 8.2. Platform
    • 8.2.1. Integrated Systems
    • 8.2.2. Library Prep Kits
  • 8.3. Predesigned Panels
    • 8.3.1. Hematological Panels
    • 8.3.2. Infectious Disease Panels
    • 8.3.3. Solid Tumor Panels

9. Gene Panel Market, by Technology

  • 9.1. Microarray
    • 9.1.1. Comparative Genomic Hybridization Arrays
    • 9.1.2. Snp Arrays
  • 9.2. Ngs
    • 9.2.1. Amplicon Sequencing
    • 9.2.2. Hybrid Capture Sequencing
  • 9.3. Pcr
    • 9.3.1. Ddpcr
    • 9.3.2. Qpcr
  • 9.4. Sanger Sequencing

10. Gene Panel Market, by Application

  • 10.1. Infectious Diseases
    • 10.1.1. Bacterial Panels
    • 10.1.2. Viral Panels
  • 10.2. Oncology
    • 10.2.1. Liquid Biopsy Panels
    • 10.2.2. Solid Tumor Panels
  • 10.3. Pharmacogenomics
  • 10.4. Rare Diseases
    • 10.4.1. Inherited Disease Panels
    • 10.4.2. Neurological Disorder Panels

11. Gene Panel Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Gene Panel Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Panel Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Panel Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Panel Market

16. China Gene Panel Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. BGI Genomics Co., Ltd.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. bioMerieux SA
  • 17.9. F. Hoffmann-La Roche Ltd.
  • 17.10. Guardant Health, Inc.
  • 17.11. Illumina, Inc.
  • 17.12. myGenomics
  • 17.13. Myriad Genetics, Inc.
  • 17.14. NanoString Technologies, Inc.
  • 17.15. Natera, Inc.
  • 17.16. Novogene Co, Ltd.
  • 17.17. PerkinElmer, Inc.
  • 17.18. PrimBio Research Institute
  • 17.19. QIAGEN N.V.
  • 17.20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE PANEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE PANEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE PANEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE PANEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE PANEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE PANEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE PANEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE PANEL MARKET SIZE, BY MULTIGENE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE PANEL MARKET SIZE, BY MULTIGENE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE PANEL MARKET SIZE, BY MULTIGENE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE PANEL MARKET SIZE, BY SINGLE GENE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE PANEL MARKET SIZE, BY SINGLE GENE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE PANEL MARKET SIZE, BY SINGLE GENE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE PANEL MARKET SIZE, BY INTEGRATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE PANEL MARKET SIZE, BY INTEGRATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE PANEL MARKET SIZE, BY INTEGRATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE PANEL MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE PANEL MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE PANEL MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE PANEL MARKET SIZE, BY HEMATOLOGICAL PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE PANEL MARKET SIZE, BY HEMATOLOGICAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE PANEL MARKET SIZE, BY HEMATOLOGICAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE PANEL MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE PANEL MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE PANEL MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE PANEL MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE PANEL MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE PANEL MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE PANEL MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE PANEL MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE PANEL MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE PANEL MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE PANEL MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE PANEL MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE PANEL MARKET SIZE, BY HYBRID CAPTURE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE PANEL MARKET SIZE, BY HYBRID CAPTURE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE PANEL MARKET SIZE, BY HYBRID CAPTURE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE PANEL MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE PANEL MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE PANEL MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE PANEL MARKET SIZE, BY DDPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE PANEL MARKET SIZE, BY DDPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE PANEL MARKET SIZE, BY DDPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE PANEL MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE PANEL MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE PANEL MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE PANEL MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE PANEL MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE PANEL MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE PANEL MARKET SIZE, BY BACTERIAL PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE PANEL MARKET SIZE, BY BACTERIAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE PANEL MARKET SIZE, BY BACTERIAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE PANEL MARKET SIZE, BY VIRAL PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE PANEL MARKET SIZE, BY VIRAL PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE PANEL MARKET SIZE, BY VIRAL PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE PANEL MARKET SIZE, BY LIQUID BIOPSY PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE PANEL MARKET SIZE, BY LIQUID BIOPSY PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE PANEL MARKET SIZE, BY LIQUID BIOPSY PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE PANEL MARKET SIZE, BY SOLID TUMOR PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE PANEL MARKET SIZE, BY INHERITED DISEASE PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE PANEL MARKET SIZE, BY INHERITED DISEASE PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE PANEL MARKET SIZE, BY INHERITED DISEASE PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE PANEL MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENE PANEL MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE PANEL MARKET SIZE, BY NEUROLOGICAL DISORDER PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE PANEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENE PANEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE PANEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE PANEL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE PANEL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE PANEL MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE PANEL MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENE PANEL MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE PANEL MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENE PANEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS GENE PANEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL GENE PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GCC GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 249. GCC GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 254. GCC GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. GCC GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 258. GCC GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. G7 GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. G7 GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 291. G7 GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. G7 GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 296. G7 GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. G7 GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 298. G7 GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. G7 GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 300. G7 GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. NATO GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 305. NATO GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. NATO GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 309. NATO GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 310. NATO GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 311. NATO GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 312. NATO GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. NATO GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 314. NATO GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL GENE PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA GENE PANEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA GENE PANEL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA GENE PANEL MARKET SIZE, BY CUSTOM PANELS, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA GENE PANEL MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA GENE PANEL MARKET SIZE, BY PREDESIGNED PANELS, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA GENE PANEL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA GENE PANEL MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA GENE PANEL MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA GENE PANEL MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA GENE PANEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA GENE PANEL MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA GENE PANEL MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA GENE PANEL MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA GENE PANEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)